Abstract
Drug transporters are now recognized as major actors in pharmacokinetics, involved notably in drug–drug interactions and drug adverse effects. Factors that govern their activity, localization and expression are therefore important to consider. In the present review, the implications of protein kinases C (PKCs) in transporter regulations are summarized and discussed. Both solute carrier (SLC) and ATP-binding cassette (ABC) drug transporters can be regulated by PKCs-related signaling pathways. PKCs thus target activity, membrane localization and/or expression level of major influx and efflux drug transporters, in various normal and pathological types of cells and tissues, often in a PKC isoform-specific manner. PKCs are notably implicated in membrane insertion of bile acid transporters in liver and, in this way, are thought to contribute to cholestatic or choleretic effects of endogenous compounds or drugs. The exact clinical relevance of PKCs-related regulation of drug transporters in terms of drug resistance, pharmacokinetics, drug–drug interactions and drug toxicity remains however to be precisely determined. This issue is likely important to consider in the context of the development of new drugs targeting PKCs-mediated signaling pathways, for treating notably cancers, diabetes or psychiatric disorders.
Highlights
Mammalian drug transporters are integral membrane proteins mediating active transport or facilitated diffusion of exogenous and endogenous compounds across cellular membranes, especially plasma membranes
We summarize the reported effects of PKCs on drug transporter activity, localization and expression
PKCs play a major, but complex, role in plasma membrane location of transporters involved in bile salt transport, i.e., NTCP, bile salt export (BSEP) and MRP2
Summary
Mammalian drug transporters are integral membrane proteins mediating active transport or facilitated diffusion of exogenous and endogenous compounds across cellular membranes, especially plasma membranes. Activation of PKCs modulates drug transporter localization in plasma membrane of polarized cells such as hepatocytes [15,16]. PKC activation impairs messenger ribonucleic acid (mRNA) and/or protein levels of drug transporters [17,18]. 1. Schematic representation of putative cellular targets of protein kinases C (PKCs, in red) with respect to regulation of drug transporter activity, localization and/or expression. Arrows in red respect to regulation of drug transporter activity, localization and/or expression. Arrows in red indicate indicate the putative effects of PKCs on transporter regulatory pathways.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.